The synergetic effect of Imipenem-clarithromycin combination in the Mycobacteroides abscessus complex

[1]  J. Mainardi,et al.  In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus , 2018, Antimicrobial Agents and Chemotherapy.

[2]  J. Mainardi,et al.  In Vitro and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against Mycobacterium abscessus , 2018, Antimicrobial Agents and Chemotherapy.

[3]  D. Deshpande,et al.  Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence , 2017, Antimicrobial Agents and Chemotherapy.

[4]  D. van Soolingen,et al.  Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection , 2016, Antimicrobial Agents and Chemotherapy.

[5]  Satoshi Mitarai,et al.  Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan , 2016, Emerging infectious diseases.

[6]  J. Mainardi,et al.  Bactericidal and intracellular activity of β-lactams against Mycobacterium abscessus. , 2016, The Journal of antimicrobial chemotherapy.

[7]  P. Polgreen,et al.  Treatment of Mycobacterium abscessus Infection , 2016, Emerging infectious diseases.

[8]  R. Wallace,,et al.  Utility of Sequencing the erm(41) Gene in Isolates of Mycobacterium abscessus subsp. abscessus with Low and Intermediate Clarithromycin MICs , 2015, Journal of Clinical Microbiology.

[9]  J. Gaillard,et al.  In vivo evaluation of antibiotic activity against Mycobacterium abscessus. , 2014, The Journal of infectious diseases.

[10]  J. Adjemian,et al.  Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. , 2014, Annals of the American Thoracic Society.

[11]  M. Kuroda,et al.  Discrimination of Mycobacterium abscessus subsp. massiliense from Mycobacterium abscessus subsp. abscessus in Clinical Isolates by Multiplex PCR , 2013, Journal of Clinical Microbiology.

[12]  M. Kostrzewa,et al.  MALDI Biotyper-Based Rapid Resistance Detection by Stable-Isotope Labeling , 2013, Journal of Clinical Microbiology.

[13]  T. Iwamoto,et al.  Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents. , 2013, International journal of antimicrobial agents.

[14]  T. Shim,et al.  Discovery of a Novel hsp65 Genotype within Mycobacterium massiliense Associated with the Rough Colony Morphology , 2012, PloS one.

[15]  R. Wallace,,et al.  Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .

[16]  J. Gaillard,et al.  Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm(41) and rrl Sequencing , 2010, Antimicrobial Agents and Chemotherapy.

[17]  Mary Ann Blosky,et al.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. , 2010, American journal of respiratory and critical care medicine.

[18]  Y. Kook,et al.  Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns , 2010, Microbiology and immunology.

[19]  J. Gaillard,et al.  Multicenter Study of Prevalence of Nontuberculous Mycobacteria in Patients with Cystic Fibrosis in France , 2009, Journal of Clinical Microbiology.

[20]  L. Saiman,et al.  Epidemiology of Nontuberculous Mycobacteria in Patients without HIV Infection, New York City , 2008, Emerging infectious diseases.

[21]  M. Kaku,et al.  In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus. , 2007, International journal of antimicrobial agents.

[22]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[23]  Ji‐Hyun Lee,et al.  Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[24]  R. Wallace,,et al.  Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms , 1992, Antimicrobial Agents and Chemotherapy.

[25]  C Thornsberry,et al.  Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae , 1985, Antimicrobial Agents and Chemotherapy.

[26]  V. Lorian.  Antibiotics in laboratory medicine , 2005 .

[27]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..